glp 1 antagonist drugs Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment GLP-1 Receptor Agonists | New
Description
The first results are expected in mid-2024
But it may not be tasty, either, Collingwood notes
Preclinical data indicated that tirzepatide exhibited an affinity for GIPR equivalent to GIP binding, while its affinity for GLP-1R was approximately five times weaker compared to GLP-1 (63)
Gonzalez-Rellan MJ et al
Orforglipron 36 mg was superior to semaglutide 14mg with respect to mean change in glycated haemoglobin (HbA1c) in patients with Type 2 diabetes inadequately controlled with metformin over 52 weeks
